Cometriq Fails to Meet Primary Endpoint in Metastatic Castration-Resistant Prostate Cancer

Cometriq Fails to Meet Primary Endpoint in Metastatic Castration-Resistant Prostate Cancer
Exelixis, Inc. has announced the results from its COMET-1 phase 3 trial on cabozantinib for the treatment of metastatic castration-resistant prostate cancer (mCRPC) did not meet the primary endpoint of overall survival (OS) when compared with prednisone treatment. Cabozantinib (COMETRIQ) is a U.S. Food and Drug Administration approved drug for the treatment of progressive, metastatic medullary

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *